News

Although right heart catheterization is an invasive procedure, it can detect changes in right ventricular volume that predict clinical worsening of pulmonary arterial hypertension. A study from the Department of Pulmonary Diseases at VU University Medical Center in Amsterdam, “Signs of Right Ventricular Deterioration in…

A research group from New York Medical College has found a gene that may control pulmonary hypertension severity, as well as the less severe form that occurs in women versus men. The article appeared November 21, 2014, in the journal Molecular Medicine. entitled, “Deletion of STAT5a/b in…

Courtesy of EchoSense Two clinical trials from EchoSense Ltd. are directed toward using lung Doppler signals (LDS) to predict the risk for pulmonary hypertension in patients with systemic sclerosis (SSc). The trials will evaluate the feasibility of identifying pulmonary vessels characteristics using LDS and EchoSense’s processing…

Actelion Pharmaceuticals Ltd., has just announced its has sent the European Medicines Agency (EMA) an application for the centralized Marketing Authorization of selexipag (Uptravi®), indicated for the treatment of pulmonary arterial hypertension (PAH). While the drug’s MAA is pending validation, the company is working…

A recent study entitled “Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience,” published in the journal Lung India, compared the clinical spectrum of diffuse parenchymal lung diseases (DPLD) with idiopathic pulmonary fibrosis…

Bayer is sponsoring a long-term observational clinical trial involving patients with pulmonary hypertension or pulmonary arterial hypertension due to scleroderma. The aim of the study is to determine the efficacy, safety, and tolerability of inhaled Ventavis (iloprost, also known as BAYQ6256) in 160 patients with either idiopathic or familial…

Corbus Pharmaceuticals Holdings, Inc. is an emerging drug development company focused on the development and commercialization of Resunab™, the company’s lead product candidate to treat rare and severe life-threatening fibrotic and inflammatory diseases such as scleroderma and cystic fibrosis.

Treating patients with systemic sclerosis (SSc) who have borderline pulmonary arterial hypertension (PAH) is vital to patient health, as life expectancy after a diagnosis of SSc-PAH is only one year. Accordingly, Heidelberg University, along with GlaxoSmithKline, initiated a clinical trial to investigate “Early Treatment…

Clinicians, scientists, and researchers have acknowledged an association between systemic sclerosis (SSc) and pulmonary arterial hypertension, and have even created the disease category “SSc-PAH,” or SSc-related PAH. This category of PAH is remarkably similar to heritable PAH, yet the basis for the similarity has remained unknown. In an effort…

Image Courtesy of TomTec Imaging Systems TomTec Imaging Systems, a Munich-based company specializing in medical imaging and information management software with a focus on ultrasound technologies, has just announced its groundbreaking 4D RV-Function© software that allows extensive assessment of the right ventricle (RV) of the heart. This diagnostic and…

When young patients develop juvenile systemic sclerosis (JSSc), it is vital to monitor them for changes in cardiopulmonary parameters that may lead to conditions such as pulmonary hypertension. However, there are no current guidelines that describe which cardiopulmonary parameters are most vital to monitor in order to screen for diseases…

RegeneRx Biopharmaceuticals, Inc. announced a recent study where company’s scientists demonstrated that Thymosin beta 4 (TB4) can reduce or even prevent heart failure in a pulmonary hypertension mouse model. The study, entitled “Thymosin Beta 4 protects mice from monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy,” was published…